Lifeward Ltd (NASDAQ: LFWD) has secured US$20 million in new capital. The Massachusetts-based company obtained the funding through a combination of equity and debt securities that it issued to two unidentified investors.
Investors learned of the transaction in a filing that Lifeward submitted to the U.S. Securities and Exchange Commission on Thursday, Apr. 2. The medtech creator intends to use the proceeds to support the ongoing development and commercialization of its mobility devices.
This fresh capital arrives just over a week after Lifeward closed its acquisition of Oratech Pharma on Mar. 25. The transaction, valued at roughly US$47 million, transfers full ownership of Oratech to Lifeward.
Through the deal, Lifeward has issued approximately 2.26 million ordinary shares, 1.3 million warrants and US$10 million in convertible notes to Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP) (FRA: OJU1). The acquisition also includes revenue-sharing rights tied to sales of Lifeward’s ReWalk exoskeleton products.
Lifeward develops and sells devices that help people with lower-limb disabilities regain mobility. Its products include the ReWalk exoskeleton, AlterG anti-gravity treadmills and MyoCycle functional electrical stimulation bikes. The company, which once operated under the name ReWalk Robotics, maintains operations in the United States, Israel and Germany.
Oratech serves as a subsidiary of Oramed Pharmaceuticals, a New York-based firm focused on turning injectable medications into oral forms. Oratech is responsible for Protein Oral Delivery (POD) technology, which protects proteins in drugs and improves their absorption in the body. Lifeward now controls this platform and can explore ways to integrate it with its current offerings. Oramed continues to manage related clinical trials under a separate agreement.
Read more: Breath Diagnostics advances pre-op pneumonia screening with FDA breakthrough designation
Acquisition expands Lifeward’s capabilities
The acquisition expands Lifeward beyond medical devices and into biotechnology, creating a more diversified business. At the same time, the US$20 million infusion adds financial resources.
This progress follows a period of notable challenges for the company. In August 2025, Lifeward received a notice from Nasdaq warning that its stock could face delisting after trading below US$1 for 30 consecutive days.
The company managed to regain compliance on Mar. 11 after completing a reverse stock split and taking other steps.
It has also dealt with ongoing cash consumption and has a relatively small market capitalization. Shares have slid by over 57 per cent within the past year.
These latest moves provide Lifeward with greater flexibility as it works to strengthen its position and address past pressures.
Read more: Prestigious medtech intelligence firm recognizes Breath Diagnostics for innovation
Follow Rowan Dunne on LinkedIn
rowan@mugglehead.com
